CFPs: Research on existing Malaria Vaccines and Development

Scope

• Proposals submitted under this topic are expected to advance knowledge on the safety, efficacy and effectiveness of currently recommended malaria vaccines or new malaria vaccines. To this end, proposals submitted under this call topic should address at least two of the following:
  • Trials should be considered, to ensure continuation of R&D on new generations of vaccines targeting all stages of plasmodium falciparum lifecycle;
  • Long term effectiveness studies through aligned primary endpoints should be considered where possible;
  • Collection, analysis and sharing of pharmacovigilance data on vaccines that are currently registered or candidates in late-stage efficacy trials.

Funding Information

• The check will normally be done for the coordinator if the requested grant amount is equal to or greater than EUR 500 000, except for:
  • public bodies (entities established as a public body under national law, including local, regional or national authorities) or international organisations; and
  • cases where the individual requested grant amount is not more than EUR 60 000 (low value grant).

Expected Outcomes

• This topic aims at supporting activities that are contributing to one or several of the expected impacts for this call. Proposals submitted under this topic should aim at delivering results that contribute to at least two of the following expected outcomes:
  • Generating evidence required for accelerating registration of new vaccine candidates;
  • Generating long-term safety and efficacy data on currently registered vaccines;
  • Safety and efficacy results from other vaccines, especially those targeting all stages of plasmodium falciparum lifecycle;
  • Generating evidence-based recommendations on how to boost manufacturing capacity and build an efficient supply chain for vaccines in general, and malaria vaccines in particular sub-Saharan Africa.

Eligible Activities

• Projects must focus exclusively on civil applications and must not:
  • aim at human cloning for reproductive purposes;
  • intend to modify the genetic heritage of human beings which could make such changes heritable (except for research relating to cancer treatment of the gonads, which may be financed);
  • intend to create human embryos solely for the purpose of research, or for the purpose of stem cell procurement, including by means of somatic cell nuclear transfer.
• Projects must, moreover, comply with EU policy interests and priorities (environment, social, security, industrial policy, etc.).
• The following activities are generally eligible for grants under Horizon Europe:
  • Research and innovation actions (RIA) — Activities that aim primarily to establish new knowledge or to explore the feasibility of a new or improved technology, product, process, service or solution. This may include basic and applied research, technology development and integration, testing, demonstration and validation of a small-scale prototype in a laboratory or simulated environment.
  • Innovation actions (IA) — Activities that aim directly to produce plans and arrangements or designs for new, altered or improved products, processes or services. These activities may include prototyping, testing, demonstrating, piloting, large-scale product validation and market replication.
  • Coordination and support actions (CSA) — Activities that contribute to the objectives of Horizon Europe. This excludes research and innovation (R&I) activities, except those carried out under the ‘Widening participation and spreading excellence’ component of the programme (part of ‘Widening participation and strengthening the European Research Area’).
  • Programme co-fund actions (CoFund) — A programme of activities established or implemented by legal entities managing or funding R&I programmes, other than EU funding bodies.
  • Innovation and market deployment actions (IMDA) — Activities that embed an innovation action and other activities necessary to deploy an innovation on the market. This includes the scaling-up of companies and Horizon Europe blended finance.
  • Training and mobility actions (TMA) — Activities that aim to improve the skills, knowledge and career prospects of researchers, based on mobility between countries and, if relevant, between sectors or disciplines.
  • Pre-commercial procurement actions (PCP) — Activities that aim to help a transnational buyers’ group to strengthen the public procurement of research, development, validation and, possibly, the first deployment of new solutions that can significantly improve quality and efficiency in areas of public interest, while opening market opportunities for industry and researchers active in Europe.
  • Public procurement of innovative solutions actions (PPI) — Activities that aim to strengthen the ability of a transnational buyers’ group to deploy innovative solutions early by overcoming the fragmentation of demand for such solutions and sharing the risks and costs of acting as early adopters, while opening market opportunities for industry.

Eligibility Criteria

• Entities eligible for funding
  • To be eligible for funding, applicants must be established in one of the following countries:
    • the Member States of the European Union, including their outermost regions:
      • Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden.
    • the Overseas Countries and Territories (OCTs) linked to the Member States:
      • Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR).
    • countries associated to Horizon Europe:
      • Albania, Armenia, Bosnia and Herzegovina, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine.
• Specific cases
  • Affiliated entities — Affiliated entities are eligible for funding if they are established in one of the countries listed above, or in a country identified in the specific call conditions.
  • Associated partners — Entities not eligible for funding (and therefore not able to participate as beneficiaries) may participate as associated partners, unless specified otherwise in the specific call conditions.
  • Coordination and Support Actions – To be eligible to participate as beneficiaries (or affiliated entities) in ‘Coordination and support’ actions, legal entities must be established in a Member State or Associated Country, unless the specific call conditions provide otherwise.
  • EU bodies — Legal entities created under EU law may also be eligible to receive funding, unless their basic act states otherwise.
  • International organisations — International European research organisations are eligible to receive funding. Unless their participation is considered essential for implementing the action by the granting authority, other international organisations are not eligible to receive funding.

For more information, visit EC.